The cost utility of solifenacin in the treatment of overactive bladder.
OBJECTIVE
Overactive bladder may cause significant discomfort to patients. The standard therapy for overactive bladder includes behavioural therapy and sometimes medication. Recently, a new medication (solifenacin 5 and 10 mg) was developed for treatment of overactive bladder. The objective of this study was to assess the cost utility of solifenacin 5 and 10 mg for overactive bladder.


METHODS
We developed a Markov model to estimate the cost per quality adjusted life years (QALY) over a period of 12-months. Model parameters were based on randomized clinical trials for solifenacin 5 and 10 mg. Data on utility scores were taken from the literature.


RESULTS
The incremental cost per QALY for solifenacin 5 mg and solifenacin 10 mg compared with placebo were 17,602 pounds and 24,464 pounds respectively. Sensitivity analyses showed that these results were robust to changes of relevant input data.


CONCLUSIONS
Solifenacin 5 and 10 mg are cost-effective treatments in patients with overactive bladder.
Hakkaart
Leona
L
Institute for Medical Technology Assessment, Erasmus MC, PO Box 1738, Rotterdam 3000 DR, The Netherlands. l.hakkaart-vanroijen@erasmusmc.nl
Verboom
Paul
P
Phillips
Richard
R
Al
Maiwenn J
MJ
D000328:Adult; D003362:Cost-Benefit Analysis; D041382:Diapers, Adult; D016527:Drug Costs; D005260:Female; D006801:Humans; D008297:Male; D008390:Markov Chains; D018727:Muscarinic Antagonists / Q000191:economics* / Q000627:therapeutic use; D010349:Patient Compliance; D019057:Quality-Adjusted Life Years; D011812:Quinuclidines / Q000191:economics* / Q000627:therapeutic use; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000191:economics* / Q000627:therapeutic use; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000191:economics
D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate